Tumor News and Research

RSS

Study focuses on nontraditional lifestyle of Retinoblastoma tumor suppressor proteins

Researchers at Michigan State University have discovered a protein that does its best work with one foot in the grave.

13 Dec 2012

Study finds many patients with family history of LINE-1 hypomethylated colorectal cancer

When people with a family history of colorectal cancer develop the disease, their tumors often carry a molecular sign that the cancer could be life-threatening and may require aggressive treatment, Dana-Farber Cancer Institute scientists report in a new study.

13 Dec 2012

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib.

From NanoString Technologies 13 Dec 2012

Review describes current state of lung cancer care

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

12 Dec 2012

U-M devises new system to capture and study circulating tumor cells

A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells that carry cancer around the body through the bloodstream.

12 Dec 2012

Oncogene-induced senescence could play a key role in future cancer therapy

Cell aging, or cellular senescence, has an important role in the natural physiological response to tumor development. Activated oncogenes are able to induce senescence, and recent findings have suggested that oncogene-induced senescence (OIS) could play a key role in future cancer therapy.

12 Dec 2012

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them. Blocking myeloid-derived suppressor cells and regulatory T-cell reconstitution improved adoptive T-cell therapy, an immunotherapy designed to suppress tumor activity.

12 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

SIRT6 protein may play a critical role in blocking cancer and controlling cellular metabolism

A new study sheds more light on how an anti-aging gene suppresses cancer growth, joint University of Michigan Health System and Harvard Medical School research shows.

11 Dec 2012

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy.

11 Dec 2012

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.

11 Dec 2012

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

11 Dec 2012

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

10 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

RET fusion signals unique NSCLC subtype

The presence of RET fusion genes in approximately 1.5% of non-small-cell lung cancer defines a subset of tumors with distinct clinicopathologic features, research suggests.

10 Dec 2012

FGFR1 amplification heralds poor prognosis in SCCL

Amplification of the fibroblast growth factor receptor 1 gene independently predicts poor outcomes in patients who have undergone resection of squamous cell lung cancer, research shows.

10 Dec 2012

New assay test shows positive results for patients with recurrent or metastatic breast cancer

When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.

10 Dec 2012

New hope for leukemia patients

Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania

10 Dec 2012

Tumor News and Research

Study focuses on nontraditional lifestyle of Retinoblastoma tumor suppressor proteins

Study finds many patients with family history of LINE-1 hypomethylated colorectal cancer

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

Review describes current state of lung cancer care

U-M devises new system to capture and study circulating tumor cells

Oncogene-induced senescence could play a key role in future cancer therapy

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

SIRT6 protein may play a critical role in blocking cancer and controlling cellular metabolism

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

RET fusion signals unique NSCLC subtype

FGFR1 amplification heralds poor prognosis in SCCL

New assay test shows positive results for patients with recurrent or metastatic breast cancer

New hope for leukemia patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News